StratiPhrenia

StratiPhrenia is a company founded in 2023 headquartered in Praha, the Czech Republic. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

StratiPhrenia is a biotechnology spin-out from the National Institute of Mental Health providing stratified diagnosis and new treatment methods for schizophrenia patients. Their technology is based on a patented discovery of three biologically distinct clusters of schizophrenia patients identified through MRI brain cortex profiles. This enables the development of a simple and clinically applicable blood biomarker panel for early-stage schizophrenia stratification.